H

Hope and Healing Cancer Services | Hinsdale, IL

Research site

(Unclaimed)

Location

950 North York Road Suite 201A, Hinsdale, Illinois, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Gemcitabine

Paclitaxel

ELU001

Carboplatin

Cisplatin

Folate

Ibrutinib

5-FU

REC-4881

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Enrolling

Solid Tumor

APC Gene Mutation

Drug: REC-4881

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Venetoclax

Drug: Ibrutinib

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.

Enrolling

Colorectal Cancer (CRC)

Melanoma

Drug: Cisplatin

Biological: GEN1042

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus